Abstract
Primary transitional cell carcinoma (TCC) localized to the urinary bladder occurs as: A, carcinoma in situ (CIS), B, superficial disease penetrating the basement membrane but not invasive of detrusor muscle, C, disease invasive of the detrusor muscle, or a mixture of these. CIS is most frequently treated with intravesical chemo or immunotherapy. Radical cystectomy is utilized for treatment failures. Superficial disease is treated by transurethral resection (TUR-BT) followed by intravesical chemo or immunotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Radwin, H.M. Radiotherapy and bladder cancer: a critical review, J. Urol.124: 43–46.
Rotman, M., Macchia, R., Silverstein, M., et al. Treatment of bladder carcinoma with concomitant infusion chemotherapy and irradiation — in this volume.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Macchia, R.J., Laungani, G. (1986). A Urologist’s Viewpoint: Treatment of Invasive Bladder Cancer by the XRT/5FU Protocol. In: Rosenthal, C.J., Rotman, M. (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2197-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2197-2_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9291-3
Online ISBN: 978-1-4613-2197-2
eBook Packages: Springer Book Archive